Biologic therapy has fundamentally transformed ankylosing spondylitis management in the United States, with the US Sacroiliitis Treatment Market reflecting the commercial dominance of anti-TNF agents, IL-17A inhibitors, and JAK inhibitors that have established the US as the world's largest and most commercially advanced AS pharmaceutical market.

FDA-approved biologics for AS — adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, secukinumab, ixekizumab, and upadacitinib — provide American rheumatologists with the broadest approved biologic armamentarium globally. The US FDA's relatively faster approval timeline compared to EMA and PMDA for some agents has historically provided American AS patients with earlier access to novel therapies, though insurance prior authorization requirements create their own access barriers independent of regulatory approval.

Commercial insurance coverage of AS biologics in the US — requiring prior authorization documentation of BASDAI or ASDAS threshold, NSAID failure, and specialist diagnosis — creates the administrative access gatekeeping that American rheumatologists navigate through prior authorization submissions. Step therapy requirements — mandating trial of specific lower-cost biologics before coverage approval for newer or preferred agents — create additional treatment sequencing constraints that American AS management involves beyond purely clinical decision-making.

The US biosimilar anti-TNF market — with multiple adalimumab biosimilars entering after the January 2023 patent cliff alongside established etanercept and infliximab biosimilars — is progressively reducing anti-TNF therapy costs that commercial insurers and PBMs (Pharmacy Benefit Managers) are leveraging through formulary preferencing to reduce biologic expenditure.

Do you think the US prior authorization system for AS biologics creates clinically inappropriate treatment delays, or does it provide necessary cost containment for the most expensive therapeutics in American rheumatology?

FAQ

What biologics are FDA-approved for ankylosing spondylitis? FDA-approved AS biologics include anti-TNF agents (adalimumab, certolizumab, etanercept, golimumab, infliximab), IL-17A inhibitors (secukinumab, ixekizumab), and the JAK inhibitor upadacitinib; all require prior authorization from most US commercial insurers before prescribing.

What is step therapy for AS biologics in the US? Step therapy requires patients to try and fail specific first-line biologic agents before insurance approves coverage of preferred or newer alternatives; many US states have enacted step therapy override laws allowing physicians to skip required steps when clinical circumstances justify it.

#USSacroiliitis #USankylosingSpondylitis #ASbiologicsUS #FDAapprovedAS #AmericanRheumatology #SpondylitisUS